Commencement of Clinical Trials, Financial Results, Upcoming Earnings Releases, and Asset Acquisitions - Research Report on Questcor, Jazz Pharmaceuticals, Ariad, and USANA PR Newswire NEW YORK, October 25, 2013 NEW YORK, October 25, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), and USANA Health Sciences Inc. (NYSE: USNA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Questcor Pharmaceuticals, Inc. Research Report On October 22, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that it will commence a Phase 2 study to explore the efficacy and safety of H.P. Acthar Gel (repository corticotropin injection) for Acute Respiratory Distress Syndrome (ARDS). According to Questcor, the Investigational New Drug (IND) application for the study has been reviewed by the U.S. Food and Drug Administration (FDA) and is now active. The Company stated that the study seek to enroll up to 210 patients in a 4-week randomized, placebo controlled trial designed to explore the efficacy and safety of several dosing regimens of Acthar in patients with moderate to severe ARDS. The Company added that the primary objective of the study will be to determine if Acthar increases the number of ventilator-free days during the 28-day treatment period. Dr. David Young, Questcor's Chief Scientific Officer, stated, "While Acthar's exact mechanism of action is unknown, based on our understanding from scientific literature and nonclinical data, we believe Acthar may be beneficial in ARDS patients via its potential anti-inflammatory and immune-modulatory properties that could reduce lung inflammation and injury, making ARDS a compelling area to investigate further." The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a415_QCOR] -- Jazz Pharmaceuticals Plc Research Report On October 22, 2013, Jazz Pharmaceuticals Plc (Jazz Pharmaceuticals) announced that it will report its Q3 2013 financial results after the market close on Tuesday, November 5, 2013. The Company informed that it will also hold a conference call on the same day at 4:30 p.m. EST/9:30 p.m. GMT to discuss quarterly results and to provide a business and financial update. The Company stated that the live webcast of the call and its replay will be available on its Investor Relations website. The Full Research Report on Jazz Pharmaceuticals Plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5fe3_JAZZ] -- Ariad Pharmaceuticals Inc. Research Report On October 22, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced that it will report its Q3 2013 financial results before the market open on Wednesday, November 6, 2013. Ariad stated that following the result release, its management will host a conference call at 8:30 a.m. ET to discuss the results and to provide a general corporate update. The Company informed that interested parties can access the live webcast of the call and its replay through its Investor Relations website. The Full Research Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/161c_ARIA] -- Oxygen Biotherapeutics, Inc. Research Report On October 21, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) announced that it has signed a Definitive Agreement to acquire certain assets of Phyxius Pharma. According to the Company, Phyxius Pharma is focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), a significant unmet medical need addressing an estimated $600 million market in the U.S. The Company informed that under the terms of the agreement, it will acquire the exclusive rights to develop and commercialize levosimendan in North America, as well as integrating three key Phyxius Pharma executives into the Company's management team. Oxygen Biotherapeutics stated that the transaction is valued at c.$4.8 million in stock as of October 18, 2013, based on Oxygen Biotherapeutics issuing an aggregate of approximately 3.4 million shares of its common stock and securities convertible into common stock to Phyxius Pharma's stockholders in a private placement. The Full Research Report on Oxygen Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5700_OXBT] -- USANA Health Sciences Inc. Research Report On October 22, 2013, USANA Health Sciences Inc. (USANA) released its Q3 2013 results with net sales reported at $173.7 million, representing a 5.2% YoY increase. The Company's net earnings were $16.8 million or $1.16 per diluted share in Q3 2013, compared to net earnings of $17.5 million or $1.18 per diluted share in Q3 2012. Dave Wentz, CEO of USANA, said, "During the third quarter, we implemented a number of strategic initiatives at our 2013 International Convention. These initiatives, which include price reductions and enhancements to our Associate compensation plan, are intended to drive long-term, sustainable customer growth for USANA." For full-year 2013, USANA anticipates consolidated net sales to range between $705 million and $710 million, and EPS to be between $5.35 and $5.40. The Full Research Report on USANA Health Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ee40_USNA] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Commencement of Clinical Trials, Financial Results, Upcoming Earnings Releases, and Asset Acquisitions - Research Report on
Press spacebar to pause and continue. Press esc to stop.